Research Disclaimer: MK-677 is sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
MK-677 (ibutamoren; Merck) is an orally active, non-peptide GH secretagogue that acts as a selective ghrelin receptor (GHS-R1a) agonist. Unlike injectable GHRP peptides (ipamorelin, GHRP-2, GHRP-6), MK-677 is orally bioavailable with a long half-life (~24 hours), enabling once-daily dosing. It stimulates pulsatile GH release from the pituitary and elevates serum IGF-1 — without suppressing endogenous GH secretion mechanisms. Its oral route, long PK profile, and extensive published human clinical data make it one of the most studied GH secretagogues in the research literature.
Table of Contents#
- Ghrelin and GHS-R1a: The Target System
- MK-677 Mechanism: GHS-R1a Agonism
- GH Pulse Profile vs. Injectable Peptides
- Pharmacokinetics: The Oral Advantage
- IGF-1 Elevation: Research Data
- Body Composition and Muscle Research
- Research Protocols
- Key References
Ghrelin and GHS-R1a: The Target System#
Ghrelin is a 28-amino acid acylated peptide hormone produced primarily in the stomach:
- Acyl modification at Ser3 (n-octanoic acid) is essential for GHS-R1a binding and GH-stimulating activity
- GHS-R1a (growth hormone secretagogue receptor 1a): expressed in hypothalamus, pituitary, hippocampus, vagus nerve
- Endogenous roles: GH secretion, appetite stimulation (orexigenic), energy metabolism, gut motility
GH secretagogue mechanism:
- Ghrelin → GHS-R1a in hypothalamus → stimulates GHRH (growth hormone-releasing hormone) neurons
- Ghrelin → GHS-R1a in pituitary → directly stimulates somatotroph GH release
- Dual site action: GHRH-dependent + direct pituitary stimulation
Synergy with GHRH: GHS-R1a agonists (ghrelin, GHRPs, MK-677) synergize with GHRH analogues (CJC-1295):
- GHRH alone → modest GH pulse
- GHS-R1a agonist alone → moderate GH pulse
- Combined → GH release 5–10× greater than either alone (synergistic, not additive)
MK-677 Mechanism: GHS-R1a Agonism#
MK-677 structure: non-peptide, small molecule (~528 Da), orally bioavailable:
- Benzolactam scaffold: designed by Merck as a peptidomimetic of GHRP-6's pharmacophore
- Binds GHS-R1a: Kd ~0.5–2 nM (similar to ghrelin)
- Selectivity: highly selective for GHS-R1a vs. other receptors at research concentrations
Downstream signaling: GHS-R1a → Gq → PLCβ → IP3 → Ca²⁺ release → protein kinase C → somatotroph depolarization → GH exocytosis
Unique property vs. other GH stimulators:
- Does NOT suppress somatostatin (unlike GHRH analogues)
- Does NOT desensitize the GH axis at normal doses (unlike supraphysiological GHRH)
- Preserves the normal pulsatile GH secretion pattern (amplifies each pulse rather than creating continuous GH)
GH Pulse Profile vs. Injectable Peptides#
| Property | MK-677 (oral) | GHRP-2 (injectable) | Ipamorelin (injectable) | CJC-1295 DAC |
|---|---|---|---|---|
| Route | Oral (once daily) | SC (2–3×/day) | SC (2–3×/day) | SC (1×/week) |
| t½ | ~24h | ~15–30 min | ~30–60 min | ~6–8 days |
| GH peak amplitude | ++++ | +++ | ++ | ++ (GHRH mechanism) |
| GH pulse frequency | Preserved natural pulses + amplitude | Acute burst at injection | Acute burst at injection | Sustained baseline elevation |
| IGF-1 effect | Sustained elevation (daily dosing) | Modest (if dosed 3×/day) | Modest | Sustained |
| Cortisol/prolactin | Moderate increase | Moderate | Minimal | Minimal |
| Appetite stimulation | Yes (significant) | Mild | Minimal | None |
MK-677's key advantage for research: once-daily oral administration produces sustained IGF-1 elevation (important for body composition and anabolic endpoint studies) without the need for multiple daily injections.
Pharmacokinetics: The Oral Advantage#
| Parameter | Value |
|---|---|
| Oral bioavailability | ~60–80% |
| t½ | ~24 hours |
| Tmax | ~2–3 hours |
| Protein binding | ~97% |
| Steady-state | ~7 days |
| Metabolism | Hepatic CYP3A4 |
| Excretion | Feces (primarily) |
Rodent PK:
- t½ ~8–12h in rats (faster clearance)
- Daily gavage maintains adequate exposure
- Typical rodent dose: 1–10 mg/kg/day oral
IGF-1 Elevation: Research Data#
From published clinical data (Merck phase 2 trials):
| Dose | IGF-1 increase vs. baseline |
|---|---|
| 10 mg/day × 4 weeks | +52% |
| 25 mg/day × 4 weeks | +79% |
| 50 mg/day × 4 weeks | +72% |
| 25 mg/day × 12 months (elderly) | +40–50% sustained |
IGF-1 elevation persists throughout treatment (no tachyphylaxis observed at 12 months in clinical studies).
Key research data: phase 2 studies in cachectic hip fracture patients and elderly subjects with functional limitation showed improved lean body mass, improved functional capacity, and increased nitrogen retention.
Body Composition and Muscle Research#
Lean mass effects:
- MK-677 25 mg/day × 12 months in elderly subjects: +2.1 kg lean mass vs. placebo
- Mechanism: GH → liver IGF-1 → systemic anabolic; local IGF-1 → satellite cell activation, protein synthesis
- mTOR pathway activation: IGF-1 → PI3K → Akt → mTOR → S6K → protein synthesis
Bone density:
- MK-677 in hip fracture patients: increased bone mineral density markers (serum osteocalcin, bone ALP)
- Potential application: osteoporosis research, fracture healing models
Adverse effects in research models:
- Water retention (common): GH effect on renal sodium/water handling
- Appetite increase (significant): GHS-R1a in hypothalamus → orexigenic
- Glucose: GH-induced insulin resistance at higher doses → glucose monitoring required
Research Protocols#
Body composition study: MK-677 in elderly rats#
| Parameter | Specification |
|---|---|
| Model | 20-month-old male SD rats (aged model) |
| Treatment | MK-677: 0, 1, 3, 10 mg/kg/day oral × 12 weeks |
| Endpoints | Serum GH (pulsatile profile by frequent blood sampling × 6h), IGF-1 (ELISA), body composition (DEXA), grip strength, food intake, fasting glucose and insulin |
MK-677 + resistance exercise synergy protocol#
| Parameter | Specification |
|---|---|
| Model | Adult male SD rats, bilateral ladder climbing resistance exercise 3×/week |
| Groups | 1. Sedentary + vehicle, 2. Exercise + vehicle, 3. Sedentary + MK-677 3 mg/kg/day, 4. Exercise + MK-677 |
| Duration | 8 weeks |
| Endpoints | Muscle cross-sectional area (gastrocnemius histology), mTOR/S6K phosphorylation (Western blot), IGF-1 receptor activation, type I/II fiber typing |
Key References#
-
Chapman IM, et al. (1996). "Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects." Journal of Clinical Endocrinology and Metabolism, 81(12):4249–4257.
-
Svensson J, et al. (1998). "Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." Journal of Clinical Endocrinology and Metabolism, 83(2):362–369.
-
Nass R, et al. (2008). "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Annals of Internal Medicine, 149(9):601–611.
Research Use Only: MK-677 is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · September 2026 · Category: Growth Hormone
